Zymogenetics (Nasdaq: ZGEN) 84.2% HIGHER; Bristol-Myers (NYSE: BMY) to acquire ZGEN for $9.75/share in cash. Click here to see the full report.

EDAP TMS SA (Nasdaq: EDAP) 50.2% HIGHER; today reported favorable clinical outcomes for patients treated with Ablatherm-HIFU. For a representative number of patients with a minimum of two year follow-up and a maximum of 15 years, the cancer specific survival rate and the freedom from metastatic disease rate were 99% and 97%, respectively, at eight years. In this study, the local control of the disease was achieved with an 85% rate of negative biopsies and a